Mater Research, Brisbane, Australia, has begun clinical trials of Novavax’s new combination coronavirus and influenza vaccine, aimed at providing protection to individuals who cannot receive an mRNA vaccine.
This non-mRNA vaccine is protein-based and contains part of the coronavirus spike protein.
It is designed to trigger an immune response by introducing a harmless portion of the coronavirus spike protein into the immune system.
Immune cells recognize the spike protein as a foreign invader and begin building defenses against it.
Eligible volunteers include healthy individuals age 65 and older who have not received an influenza vaccine in the past two months.
The trial will begin on November 4 and last for three weeks.
The trial is recruiting 150 participants, a representative from Mater Research’s Respiratory, Infectious Disease, and Thoracic Oncology (RIO) division confirmed.
Mater Research’s RIO Clinical Trials Division currently manages more than 20 clinical trials focused on respiratory health.
Professor Paul Griffin, Director of the Mater Center for Infectious Diseases, is the lead investigator on the trial.
Just 559,000 of Queenslanders’ 5.56 million people received a COVID-19 vaccine last year, while flu vaccinations are down compared to the previous year’s free flu vaccination campaign, with 1.7 million doses administered this year. vaccinations have been carried out, the institute noted.
Professor Griffin said: “We know that the majority of people are currently undervaccinated against both influenza and COVID-19. By offering people the option of an approved combination vaccine, we are We hope this will encourage uptake of the vaccine as it will no longer require two shots.
“We know that there are many people who cannot or do not want to receive an mRNA vaccine. By participating in this trial, we will ensure that people have access to a non-mRNA option as part of the trial and will This will give us the data to make an informed approval decision.”
“Meter Research Begins Pandemic Influenza Combination Vaccine Trial” was originally created and published by Clinical Trials Arena, a brand owned by GlobalData.
The information on this site is published in good faith and for general information purposes only. It is not intended to constitute advice on which you should rely, and we make no representations or warranties of any kind, express or implied, as to its accuracy or completeness. You should obtain professional or specialist advice before taking or refraining from taking any action on the basis of the content on our site.
